ENTX stock forecast, quote, news & analysis
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins... Show more
Entera Bio (ENTX) Stock Analysis: Oral Osteoporosis Drug EB613 Advances Toward Pivotal Phase 3 Trial
Key Takeaways
- Entera Bio shares moved roughly 2% higher over the trailing 30 days, a relatively contained move as the market digested a wave of new analyst coverage.
- The company's lead candidate, EB613, an oral parathyroid hormone tablet for osteoporosis, is advancing toward a registrational Phase 3 study planned for late 2026.
- A $275 million oversubscribed private placement led by BVF Partners L.P. is expected to fund the EB613 program through an anticipated New Drug Application submission and extend the cash runway into 2030.
- Several analysts initiated coverage in September 2026, including Guggenheim (Buy), Cantor Fitzgerald (Overweight), and Leerink Partners (Outperform).
- As a clinical-stage biotech, Entera Bio reports no product revenue, and its valuation reflects pipeline execution risk tied primarily to EB613.
Current Market Snapshot
Entera Bio Ltd. (NASDAQ: ENTX) has traded in a relatively narrow band in recent weeks, closing near $3.02 after a roughly 2% move over the trailing 30 days. The stock touched a recent peak above $3.47 in late August before pulling back, reflecting the typical volatility of clinical-stage biotech names where sentiment shifts alongside development milestones and financing updates.
Investor attention remains focused on the company's flagship program rather than near-term financial results. With no product revenue, Entera Bio is valued primarily on the clinical and commercial potential of its oral peptide platform, particularly EB613. The wave of September analyst initiations—led by Guggenheim's Buy rating and $11 price target—has reinforced the stock's role as a development-stage story centered on osteoporosis treatment.
Entera Bio (ENTX) Business Overview and Competitive Position
Entera Bio is a clinical-stage biotechnology company based in Israel that develops orally delivered large-molecule and peptide therapeutics using its proprietary N-Tab platform. The company's core value proposition is converting treatments traditionally administered by injection into once-daily oral tablets, potentially improving patient convenience and compliance.
Its most advanced candidate is EB613, an oral human parathyroid hormone (PTH 1-34) being developed as a bone-building treatment for postmenopausal osteoporosis. A placebo-controlled Phase 2 study met its primary and secondary endpoints on bone mineral density. The pipeline also includes EB612 for hypoparathyroidism and, in collaboration with OPKO Health, oral peptide candidates targeting obesity and rare malabsorption conditions.
Recent Developments Driving ENTX
Several verified developments have shaped sentiment around Entera Bio. The company reported second-quarter 2026 results showing a net loss of $7.3 million, or $0.14 per share, with zero revenue, while research and development spending roughly doubled as the company prepared EB613 for late-stage trials.
The most consequential catalyst was the announcement of an oversubscribed $275 million private placement led by BVF Partners L.P., which management expects to fund EB613 through a potential New Drug Application submission and extend the cash runway into 2030. In June 2026, Entera Bio reached alignment with the U.S. Food and Drug Administration on a single 12-month registrational Phase 3 trial in approximately 750 postmenopausal women, with total hip bone mineral density as the primary endpoint.
On the analyst front, Guggenheim initiated coverage with a Buy rating and an $11 price target in September 2026, following Cantor Fitzgerald (Overweight) and Leerink Partners (Outperform). The company also strengthened its leadership team, appointing Dr. Riccardo Paolo Camisasca as Chief Medical Officer in August 2026.
Trending AI Robots
For traders seeking a data-driven approach to market opportunities, Tickeron's Trending AI Robots page offers a curated view of the platform's artificial intelligence trading tools. Tickeron provides hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots appear in this dedicated section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches that range from short-term momentum signals to longer-horizon trend models. The curated list is designed to help traders identify systems with demonstrated recent performance. Visitors can review the available bots to find strategies that align with their own trading objectives and risk preferences.
2026 Outlook and What Investors Should Watch
The primary catalyst on Entera Bio's horizon is the initiation of the EB613 Phase 3 trial, planned for late 2026, with topline data anticipated in the second half of 2028. Successful execution of the study would represent a major validation of the company's oral delivery platform. Investors should also monitor progress on the EB612 program, where an investigational new drug filing is planned for the first half of 2027.
Financially, the $275 million private placement meaningfully de-risks the company's near-term balance sheet, with management guiding for a runway into 2030. A special shareholder meeting scheduled for November 2026 will address equity incentive proposals tied to the financing. As a pre-revenue biotech, Entera Bio remains sensitive to clinical setbacks, regulatory decisions, and dilution from future capital raises, and its valuation continues to depend on execution across the oral peptide pipeline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ENTX's RSI Indicator ascends from oversold territory
The RSI Indicator for ENTX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ENTX as a result. In 78 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for ENTX just turned positive on October 16, 2026. Looking at past instances where ENTX's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
ENTX moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for ENTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ENTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ENTX's P/B Ratio (72.679) is slightly higher than the industry average of (2.988). P/E Ratio (-8.714) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1428.571) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of flu medicines
Industry Biotechnology